Americas Committee for Treatment and Research in Multiple Sclerosis

Overview of Tolebrutinib’s Positive 18-Month Data in Relapsing MS: Jiwoh Oh, MD, PhD

March 10, 2022

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]